Results 71 to 80 of about 7,028 (198)

Upadacitinib versus Tofacitinib in the Management of Ulcerative Colitis: A Systematic Review and Meta-Analysis

Inflammatory Intestinal Diseases
Introduction: Upadacitinib and tofacitinib, oral Janus kinase inhibitors, have demonstrated efficacy and safety in ulcerative colitis (UC) in clinical trials. However, real-world comparative data are limited.
Tareq Alsaleh, Abdul Mohammed, Aimen Farooq, Magda Elamin, Amr Akl, Karim Mohamed Yassin, Ahmed Elnaggar, Jennifer Seminerio   +7 more
doaj   +1 more source

Development of an UPLC-MS/MS Method for the Quantitative Analysis of Upadacitinib in Beagle Dog Plasma and Pharmacokinetics Study

Drug Design, Development and Therapy, 2021
Meng-Jie Wang,1 Yu-Hang Zhao,2 Chen Fan,3 Ying-Jie Wang,3 Xin-Qi Wang,3 Xiang-Jun Qiu,3 Rui-Le Shen1 1Department of Neurology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan ...
Wang MJ, Zhao YH, Fan C, Wang YJ, Wang XQ, Qiu XJ, Shen RL   +6 more
doaj  

Off-label use of upadacitinib in dermatology: a review [PDF]

Objectives Upadacitinib, a selective JAK1 inhibitor, is approved for the treatment of atopic dermatitis but is increasingly used off-label in dermatology.
Xiaoli Ni, Hongtao Yu, Zhen Mu, Junkai Zhu, Kaiyu Yu   +4 more
core   +1 more source

European Society of Contact Dermatitis Guideline for Diagnostic Patch Testing—Recommendations on Best Practice (Update 2026)

Contact Dermatitis, EarlyView.
ABSTRACT The present guideline updates the initial ESCD patch testing guideline, summarizing all aspects of patch testing for the diagnosis of contact allergy in patients suspected of suffering, or having been suffering, from allergic contact dermatitis or other delayed‐type hypersensitivity skin and mucosal conditions. Sections with brief descriptions
Wolfgang Uter, Olivier Aerts, Tove Agner, Richard Brans, Magnus Bruze, Alicia Cannavó, Marie‐Noёlle Crépy, Ana M. Giménez‐Arnau, Margarida Gonçalo, An Goossens, Swen M. John, Carola Lidén, Suzana Ljubojević Hadžavdić, Vera Mahler, Mihaly Matura, Esen Özkaya, Maria Pesonen, Nadia Raison‐Peyron, Thomas Rustemeyer, Radoslaw Spiewak, Luca Stingeni, Ian R. White, S. Mark Wilkinson, Jeanne Duus Johansen   +23 more
wiley   +1 more source

Treatment of rosacea with upadacitinib and abrocitinib: case report and review of evidence for Janus kinase inhibition in rosacea

Frontiers in Immunology
IntroductionConventional rosacea treatments are not uniformly pervasive, and the adverse reactions can potentially constrain their utility. The clinical use of JAK1 inhibitors upadacitinib and abrocitinib in the treatment of refractory rosacea has rarely
Ting Zhang, Xu Liu, Lu Zhang, Xian Jiang, Xian Jiang   +4 more
doaj   +1 more source

Elevated IL‐4 and IL‐13 Expression in Hailey‐Hailey Disease: Evidence for Th2‐Mediated Pathogenesis and Targeted Treatment

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Hailey‐Hailey disease (HHD) is a rare autosomal dominant blistering disorder caused by mutations in the ATP2C1 gene, which impair keratinocyte adhesion through disrupted calcium signaling. While traditionally considered a structural defect, recent studies suggest that Th2‐mediated inflammation may exacerbate disease pathology ...
Simonetta I. Gaumond, Victoria Soto, Beatriz Abdo Abujamra, Franco Rongioletti, John A. McGrath, Ivan Jozic, Paolo Romanelli   +6 more
wiley   +1 more source

Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series [PDF]

Xin He,1,2 Dongyue Yang,1,2 Lingyao Lai,1,2 Jing Lang,1,2 Kebo Wei,1,2 Min Xiao1 1Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People’s Republic of China; 2School of Clinical ...
Lang J, Xiao M, He X, Yang D, Lai L, Wei K   +5 more
core  

Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial

RMD Open
Objective To assess the long-term safety and efficacy of upadacitinib over 5 years in Japanese patients with moderate-to-severe active rheumatoid arthritis and an inadequate response to stable doses of conventional synthetic disease-modifying ...
Tsutomu Takeuchi, Hideto Kameda, Yoshiya Tanaka, Mitsuhiro Kawano, Motohiro Oribe, Kunihiro Yamaoka, Heidi S Camp, Yuko Konishi, Sumi Chonan, Kimitoshi Ikeda   +9 more
doaj   +1 more source

S3 guideline diagnostics and therapy in alopecia areata – Part 2: Therapy, psychosocial and cosmetic support

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review [PDF]

Luciano Ibba,1,2 Luigi Gargiulo,1,2 Carlo Alberto Vignoli,1,2 Giovanni Fiorillo,1,2 Mario Valenti,1,2 Antonio Costanzo,1,2 Alessandra Narcisi1 1Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy; 2Department of Biomedical Sciences ...
Ibba L, Valenti M, Fiorillo G, Narcisi A, Vignoli CA, Costanzo A, Gargiulo L   +6 more
core